Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.39 |
| ▸ | NOS3 | P29474 | 5/20 | 0.34 |
| ▸ | NOS1 | P29475 | 5/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 3/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21923110 | 0.78 | GABRG2 (0.46) | ENPP2MRGPRX4GRM5 | |
| SCHEMBL21922389 | 0.77 | ENPP2 (0.46) | ENPP2GRM5 | |
| SCHEMBL21923113 | 0.74 | ENPP2 (0.46) | ENPP2 | |
| SCHEMBL21922353 | 0.73 | ENPP2 (0.46) | ENPP2GRM5 | |
| SCHEMBL22186143 | 0.69 | ALDH1A1 (0.30) | — | |
| SCHEMBL1993677 | 0.68 | PGR (0.44) | S1PR1SCN5ASCN9APGR | |
| SCHEMBL932624 | 0.67 | S1PR1 (0.37) | ENPP2S1PR1SCN5ASCN9APGR | |
| SCHEMBL21922352 | 0.67 | GAA (0.53) | — | |
| SCHEMBL931898 | 0.67 | FFAR4 (0.43) | ENPP2S1PR1SCN5ASCN9AGRM5 | |
| SCHEMBL17125226 | 0.67 | PGR (0.39) | SCN5ASCN9AGRM5PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200131151-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131151-A1 | NOVEL PYRIDAZINES | ENPP2, PLPBP, PRDX6 | ENPP2 1/4885S1PR1 1015/4885NOS3 4372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.